|
rs113488022
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Our results reveal a common BRAF(V600E)-directed transcriptional regulatory pathway that mediates epigenetic silencing in unrelated solid tumors and provide strong support for an instructive model of oncoprotein-directed epigenetic silencing.
|
26787892 |
2016 |
|
rs113488022
|
|
|
0.030 |
GeneticVariation |
BEFREE |
This study evaluated the safety and tolerability, pharmacokinetics (PK) and preliminary efficacy of dabrafenib 150 mg b.i.d. plus trametinib 2 mg q.d. in Japanese patients with BRAF V600E/K mutant solid tumors (phase 1) and melanoma (phase 2).
|
29399853 |
2018 |
|
rs113488022
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Precision Medicine Intelligence - evidence scoring evaluating the clinical actionability of BRAF V600E in multiple non-melanoma solid tumors.
|
27540599 |
2016 |
|
rs121434592
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Results In patients with AKT1 E17K-mutant tumors (n = 52) and a median of five lines of prior therapy, the median PFS was 5.5 months (95% CI, 2.9 to 6.9 months), 6.6 months (95% CI, 1.5 to 8.3 months), and 4.2 months (95% CI, 2.1 to 12.8 months) in patients with estrogen receptor-positive breast, gynecologic, and other solid tumors, respectively.
|
28489509 |
2017 |
|
rs121434592
|
|
|
0.030 |
GeneticVariation |
BEFREE |
AKT1(E17K) mutations occur at low frequency in a variety of solid tumors, including those of the breast and urinary bladder.
|
26351323 |
2015 |
|
rs121434592
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Here, we selectively disrupt the ability of rapidly proliferating cancer cells to spawn AKT1<sup>low</sup> daughter cells that are rare, slowly proliferating, tumor-initiating, and chemotherapy-resistant, using β1-integrin activation and the AKT1-E17K-mutant oncoprotein as experimental tools <i>in vivo</i> Surprisingly, we find that selective depletion of AKT1<sup>low</sup> slow proliferators actually reduces the growth of a molecularly diverse panel of human cancer cell xenograft models without globally altering cell proliferation or survival <i>in vivo</i> Moreover, we find that unusual cancer patients with AKT1-E17K-mutant solid tumors also fail to produce AKT1<sup>low</sup> quiescent cancer cells and that this correlates with significantly prolonged survival after adjuvant treatment compared with other patients.
|
29054988 |
2018 |
|
rs121913377
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Our results reveal a common BRAF(V600E)-directed transcriptional regulatory pathway that mediates epigenetic silencing in unrelated solid tumors and provide strong support for an instructive model of oncoprotein-directed epigenetic silencing.
|
26787892 |
2016 |
|
rs121913377
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Precision Medicine Intelligence - evidence scoring evaluating the clinical actionability of BRAF V600E in multiple non-melanoma solid tumors.
|
27540599 |
2016 |
|
rs121913377
|
|
|
0.030 |
GeneticVariation |
BEFREE |
This study evaluated the safety and tolerability, pharmacokinetics (PK) and preliminary efficacy of dabrafenib 150 mg b.i.d. plus trametinib 2 mg q.d. in Japanese patients with BRAF V600E/K mutant solid tumors (phase 1) and melanoma (phase 2).
|
29399853 |
2018 |
|
rs758272654
|
|
|
0.020 |
GeneticVariation |
BEFREE |
GNAS T393C has been shown to predict the postoperative course in solid tumors and may therefore be useful for treatment stratification.
|
24986238 |
2014 |
|
rs758272654
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Recent studies have shown an association between the GNAS1 T393C polymorphism and clinical outcome for various solid tumors.
|
19274060 |
2009 |
|
rs1042522
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Among the natural sequence variants of TP53, rs1042522 (R72P) modifies the risk for solid tumors.
|
19837266 |
2009 |
|
rs1057519865
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The specificity of the FOXL2 c.402C>G somatic mutation: a survey of solid tumors.
|
19956657 |
2009 |
|
rs10889677
|
|
|
0.010 |
GeneticVariation |
BEFREE |
These findings demonstrated that the IL-23R rs10889677</span> genetic variant might play an important part during malignant transformation of multiple solid tumors.
|
24278297 |
2013 |
|
rs1131691014
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Among the natural sequence variants of TP53, rs1042522 (R72P) modifies the risk for solid tumors.
|
19837266 |
2009 |
|
rs11547328
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Absence of R24C mutation of the CDK4 gene in leukemias and solid tumors.
|
12731669 |
2003 |
|
rs11614913
|
|
|
0.010 |
GeneticVariation |
BEFREE |
As there are no previous studies on the miR-196a2 variant or expression in any type of cancer among our population, we aimed to determine the expression profile of mature miR-196a2 in various types of solid tumors and to analyze the impact of its polymorphism (rs11614913; C/T) on the expression levels.
|
27342110 |
2016 |
|
rs121913409
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The p.S45F activating mutation was found in a variety of solid tumors, and accounts for 3.3 to 10.4% of all known β-catenin mutations.
|
28725522 |
2017 |
|
rs1284806277
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Moreover, the most recent data reveal that expression of S100P is up-regulated by activation of glucocorticoid receptor suggesting that S100P could play a role in therapy resistance mediated by glucocorticoids in solid tumors.
|
20155429 |
2011 |
|
rs1285136498
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Moreover, the most recent data reveal that expression of S100P is up-regulated by activation of glucocorticoid receptor suggesting that S100P could play a role in therapy resistance mediated by glucocorticoids in solid tumors.
|
20155429 |
2011 |
|
rs1353702185
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Among the natural sequence variants of TP53, rs1042522 (R72P) modifies the risk for solid tumors.
|
19837266 |
2009 |
|
rs1799945
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Therefore, this meta-analysis was conducted to summarize the effect of the H63D variant on the incidence of solid tumor.
|
26535689 |
2015 |
|
rs1979277
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A comprehensive search was conducted to identify all eligible studies of the SHMT1 rs1979277 polymorphism and solid tumor</span> risk.
|
26125758 |
2015 |
|
rs2736100
|
|
|
0.010 |
GeneticVariation |
BEFREE |
TERT rs2736100_C polymorphism predisposes to the development of BCR-ABL1-negative MPN with the co-occurrence of solid tumors, especially with the usage of cytoreductive treatment.
|
26487696 |
2016 |
|
rs397507509
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The association of this p.G60A PTPN11 mutation with neuroblastoma provides new evidence that gain of function PTPN11 mutations may play an important role in the pathogenesis of solid tumors associated with Noonan syndrome.
|
18328949 |
2008 |